Judge Finds Warner-Lambert Accupril Patent Enabled

Law360, New York (December 3, 2007, 12:00 AM EST) -- A federal judge has ruled that claims of the patent involved in a long-standing dispute between Warner-Lambert Co. and generic maker Teva Pharmaceuticals USA Inc. are enabled, rejecting Teva’s theory of invalidity.

Following a bench trial on the matter in May, Judge Dickinson R. Debevoise of the U.S. District Court for the District of New Jersey ruled Thursday that claims in Warner-Lambert’s U.S. Patent Number 4,743,450 were enabled, despite Teva’s arguments that the patent’s vast claims and lack of guidance resulted in a failure to meet...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.